Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Part A: randomized, double-blind, sequential. Part B: randomized, open-label, cross-over.
Age
18–45
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m\^2) at the Screening Visit and at the Safety Baseline/Baseline Visit.
The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, vital signs, a safety ECG, and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.
You may not be if
The participant has taken disallowed medication \<1 week prior to the first dose of study drug or \<5 half-lives prior to the Screening Visit for any medication taken.
The participant has orthostatic hypotension, defined as a decrease in systolic blood pressure ≥20 millimeters of mercury (mmHg) and/or a decrease in diastolic blood pressure ≥10 mmHg from supine to standing, at the Screening Visit or at the Safety Baseline/Baseline Visit.
The participant has a QTcF interval \>450 milliseconds (ms) at the Screening Visit or at the Safety Baseline/Baseline Visit, as calculated by the ECG equipment and evaluated by the investigator.
The participant has taken any investigational medicinal product \<3 months prior to the first dose of study drug.
The participant has received an injection of COVID-19 vaccination less than 30 days prior to the first dose of study drug.
